Xue J M, Shi M
Department of Materials Science, National University of Singapore, 117543, Singapore.
J Control Release. 2004 Aug 11;98(2):209-17. doi: 10.1016/j.jconrel.2004.04.023.
In this paper, we report a poly(D,L-lactide-co-glycolide) (PLGA)/mesoporous silica hybrid structure (PS hybrid structure), which was synthesized via a novel sol-gel route assisted by single emulsion solvent evaporation. The in intro drug release properties of both the mesoporous silica and the PS hybrid structure were investigated. It was observed that gentamicin-loaded mesoporous silica showed a sharp initial burst during the first day followed by a rather constant and low release over the subsequent period of 3 weeks. In comparison with the mesoporous silica without biodegradable polymer encapsulation, the PS hybrid structure could realize a reduced initial burst, with a plateau stage for nearly 3 weeks of slow release, followed by a sustained release stage lasting for nearly 2 weeks. The whole release period could last as long as 5 weeks. These distinct behaviors make the hybrid structure material promising as a new drug release material for bone filling applications.
在本文中,我们报道了一种聚(D,L-丙交酯-共-乙交酯)(PLGA)/介孔二氧化硅杂化结构(PS杂化结构),它是通过一种新型的单乳液溶剂蒸发辅助溶胶-凝胶路线合成的。研究了介孔二氧化硅和PS杂化结构的体外药物释放特性。观察到载有庆大霉素的介孔二氧化硅在第一天出现急剧的初始突释,随后在接下来的3周内释放相当恒定且缓慢。与未用可生物降解聚合物封装的介孔二氧化硅相比,PS杂化结构可以实现初始突释的减少,具有近3周缓慢释放的平稳阶段,随后是持续近2周的缓释阶段。整个释放期可以长达5周。这些独特的行为使得该杂化结构材料有望成为用于骨填充应用的新型药物释放材料。